Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Candel Therapeutics has initiated the global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec plus valacyclovir in combination with pembrolizumab for advanced non-small cell lung cancer. The randomized open-label trial plans to enroll patients across more than 150 sites with a primary endpoint of overall survival, comparing the regimen against standard-of-care docetaxel.
Key figures
- Drug Name
- aglatimagene besadenovec (CAN-2409)
- Phase Of Trial
- Phase 3
- Trial sites
- 150
- Randomization ratio
- 1:1
- Phase 2 median os months
- 25.4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.